All relevant data are within the paper.

Introduction {#sec001}
============

Combined estrogen-progestin preparations (CEPs) are one of the most commonly used birth control methods worldwide. CEPs have benefits beyond preventing an undesired pregnancy, including reduced ovarian and endometrial cancer risk, reduced dysfunctional uterine bleeding, decreased menstrual flow and menorrhagia, decreased primary dysmenorrhea, improved hirsutism and acne, and decreased risk of premenstrual syndrome/premenstrual dysphoric disorder \[[@pone.0182045.ref001]\].

Because CEPs are administered to healthy women over the long-term, patients should be carefully monitored for adverse events (AEs). CEPs, such as oral contraceptives (OCs), have a variety of side effects, of which thrombosis is the most frequent and important \[[@pone.0182045.ref002]\]. Numerous studies have demonstrated a relationship between CEPs and thromboembolism (TE), including venous thromboembolism (VTE) \[[@pone.0182045.ref001]--[@pone.0182045.ref015]\]. According to the American College of Obstetricians and Gynecologists, the incidence of TE increases from 1 to 5 occurrences per 10,000 women per year in non-OC users to 3 to 9 occurrences per 10,000 women per year in OC users \[[@pone.0182045.ref016]\]. A systematic review indicated that the risk of VTE in women of childbearing age who were non-OC users was 4 per 10,000 women per year, whereas in OC users, the risk was 7 to 10 per 10,000 women per year \[[@pone.0182045.ref004]\]. Appropriate treatment of TE after onset resolves the thrombus; however, in approximately 20%--50% of cases of TE, and in proximal deep vein thrombosis (DVT) to a greater extent, patients develop a post-thrombotic syndrome with lifelong problems including pain and swelling of the leg \[[@pone.0182045.ref017],[@pone.0182045.ref018]\]. Rare thrombi cause pulmonary embolism, and 1 in 100 cases results in death \[[@pone.0182045.ref013]\].

Few studies have examined the association between CEP use and arterial thromboembolism (ATE), such as myocardial infarction and ischemic stroke \[[@pone.0182045.ref002],[@pone.0182045.ref010],[@pone.0182045.ref019]--[@pone.0182045.ref023]\]. Although ATE is less frequent than VTE, the consequences of ATE are often more serious \[[@pone.0182045.ref023]\]. The World Health Organization (WHO) has reported that the use of CEPs increased the risk of myocardial infarction by approximately 5-fold and the risk of ischemic stroke by approximately 3-fold \[[@pone.0182045.ref002],[@pone.0182045.ref019],[@pone.0182045.ref020]\].

Because VTE and ATE are rare AEs associated with CEP use, the implementation phase of epidemiologic research is difficult. The Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has released the Japanese Adverse Drug Event Report (JADER) database, which is a large spontaneous reporting system (SRS) and reflects the realities of clinical practice in Japan \[[@pone.0182045.ref024]\]. Therefore, JADER has been used for pharmacovigilance assessments for rare AEs using the reporting odds ratio (ROR) \[[@pone.0182045.ref024]--[@pone.0182045.ref027]\].

Several studies have indicated that the risk of developing CEP-induced VTE is greatest during the first year of use \[[@pone.0182045.ref002],[@pone.0182045.ref004],[@pone.0182045.ref006],[@pone.0182045.ref007],[@pone.0182045.ref009],[@pone.0182045.ref010],[@pone.0182045.ref012]\]. However, detailed onset profiles of CEP-induced VTE are not clear. The analysis of time-to-onset data has been proposed as a new method of detecting signals for AEs in SRSs \[[@pone.0182045.ref024],[@pone.0182045.ref027],[@pone.0182045.ref028]\]. In this study, we applied the index of ROR to TE and evaluated time-to-onset profiles of TE for CEPs in the real world.

Furthermore, association rule mining has been proposed as a new analytical approach for identifying undetected clinical factor combinations, such as possible risk factors, between variables in huge databases \[[@pone.0182045.ref029]--[@pone.0182045.ref031]\]. This is the first application of association rule mining for the detection of association rules between CEPs and TE.

Materials and methods {#sec002}
=====================

AEs recorded from April 2004 to November 2014 in the JADER database were obtained from the PMDA website ([www.pmda.go.jp](http://www.pmda.go.jp)). The JADER database consists of 4 tables: patient demographic information, such as sex, age, and reporting year (demo); drug information, such as non-proprietary name of the prescribed drug, route, and start and end date of administration (drug); adverse events, such as type, outcome, and onset date (reac); and primary disease (hist). We constructed a relational database that integrated the 4 data tables using FileMaker Pro 12 software (FileMaker, Inc., Santa Clara, CA, USA). The "drug" file included the role codes assigned to each drug: suspected, concomitant, and interacting drugs (higiyaku, heiyouyaku, and sougosayou in Japanese, respectively). The suspected drug records were extracted and analyzed in this study.

Five CEPs (drospirenone combined with ethinyl estradiol (EE, Dro-EE), norethisterone with EE (Ne-EE), levonorgestrel with EE (Lev-EE), desogestrel with EE (Des-EE), and norgestrel with EE (Nor-EE)) were assessed. Since EE is not a constituent of Menoaid (ASKA Pharmaceutical Co., Ltd., Tokyo, Japan) and Wellnara (Bayer Yakuhin, Ltd., Osaka, Japan), they were excluded in the analysis. The number of reported cases of E·P·Hormone depot (ASKA Pharmaceutical Co., Ltd., Tokyo, Japan), Lutes depot (Mochida Pharmaceutical Co., Ltd., Tokyo, Japan), Lutedion (ASKA Pharmaceutical Co., Ltd., Tokyo, Japan), and Sophia (ASKA Pharmaceutical Co., Ltd., Tokyo, Japan) were low and, therefore, they were not assessed in the analysis.

AEs in the JADER database are coded according to the terminology preferred by the Medical Dictionary for Regulatory Activities/Japanese version 17.1 (MedDRA/J) ([www.pmrj.jp/jmo/php/indexj.php](http://www.pmrj.jp/jmo/php/indexj.php)). The standardized MedDRA Queries (SMQ) index consists of groupings of MedDRA terms, ordinarily at the preferred term (PT) level, that relate to a defined medical condition or area of interest \[[@pone.0182045.ref032]\]. We used the SMQ for embolic and thrombotic events, arterial (SMQ code: 20000082), embolic and thrombotic events, vessel type unspecified and mixed arterial and venous (SMQ code: 20000083), and embolic and thrombotic events, venous (SMQ code: 20000084; [Table 1](#pone.0182045.t001){ref-type="table"}).

10.1371/journal.pone.0182045.t001

###### Preferred terms of thromboembolism associated with combined estrogen-progestin preparations in MedDRA [^a)^](#t001fn001){ref-type="table-fn"}.

![](pone.0182045.t001){#pone.0182045.t001g}

  Embolic and thrombotic events, arterial   Embolic and thrombotic events, vessel type unspecified and mixed arterial and venous   Embolic and thrombotic events, venous                                                                  
  ----------------------------------------- -------------------------------------------------------------------------------------- --------------------------------------- --------------------------------------------------- ---------- --------------------------------------
  10074337                                  Acute aortic syndrome                                                                  10075178                                Adrenal thrombosis                                  10003880   Axillary vein thrombosis
  10000891                                  Acute myocardial infarction                                                            10060956                                Angiogram abnormal                                  10006537   Budd-Chiari syndrome
  10001902                                  Amaurosis                                                                              10052906                                Angiogram cerebral abnormal                         10052698   Catheterisation venous
  10001903                                  Amaurosis fugax                                                                        10057517                                Angiogram peripheral abnormal                       10007830   Cavernous sinus thrombosis
  10002475                                  Angioplasty                                                                            10058562                                Arteriovenous fistula occlusion                     10053377   Central venous catheterisation
  10057617                                  Aortic bypass                                                                          10003192                                Arteriovenous fistula thrombosis                    10008138   Cerebral venous thrombosis
  10002897                                  Aortic embolus                                                                         10048632                                Atrial thrombosis                                   10053681   Compression stockings application
  10061651                                  Aortic surgery                                                                         10071043                                Basal ganglia stroke                                10051055   Deep vein thrombosis
  10002910                                  Aortic thrombosis                                                                      10049824                                Bone infarction                                     10066881   Deep vein thrombosis postoperative
  10057794                                  Aortogram abnormal                                                                     10074422                                Brain stem embolism                                 10014522   Embolism venous
  10071026                                  Arterectomy                                                                            10006147                                Brain stem infarction                               10058991   Hepatic vein occlusion
  10003140                                  Arterectomy with graft replacement                                                     10068644                                Brain stem stroke                                   10019713   Hepatic vein thrombosis
  10056418                                  Arterial bypass operation                                                              10062573                                Brain stem thrombosis                               10051031   Homans\' sign positive
  10061655                                  Arterial graft                                                                         10053994                                Cardiac ventricular thrombosis                      10058992   Iliac vein occlusion
  10062599                                  Arterial occlusive disease                                                             10067167                                Cerebellar embolism                                 10070911   Inferior vena cava syndrome
  10061657                                  Arterial stent insertion                                                               10008034                                Cerebellar infarction                               10058987   Inferior vena caval occlusion
  10052949                                  Arterial therapeutic procedure                                                         10008118                                Cerebral infarction                                 10061251   Intracranial venous sinus thrombosis
  10003178                                  Arterial thrombosis                                                                    10008119                                Cerebral infarction foetal                          10023237   Jugular vein thrombosis
  10061659                                  Arteriogram abnormal                                                                   10008120                                Cerebral ischaemia                                  10075428   Mahler sign
  10003195                                  Arteriogram carotid abnormal                                                           10070671                                Cerebral septic infarct                             10069727   May-Thurner syndrome
  10063025                                  Atherectomy                                                                            10008132                                Cerebral thrombosis                                 10027402   Mesenteric vein thrombosis
  10069020                                  Basal ganglia infarction                                                               10052173                                Cerebrospinal thrombotic tamponade                  10027403   Mesenteric venous occlusion
  10048963                                  Basilar artery occlusion                                                               10008190                                Cerebrovascular accident                            10029925   Obstetrical pulmonary embolism
  10063093                                  Basilar artery thrombosis                                                              10049165                                Cerebrovascular accident prophylaxis                10073708   Obstructive shock
  10005184                                  Blindness transient                                                                    10008196                                Cerebrovascular disorder                            10074349   Ophthalmic vein thrombosis
  10069694                                  Brachiocephalic artery occlusion                                                       10051902                                Cerebrovascular operation                           10072059   Ovarian vein thrombosis
  10067744                                  Capsular warning syndrome                                                              10057403                                Choroidal infarction                                10050216   Paget-Schroetter syndrome
  10071260                                  Carotid angioplasty                                                                    10069729                                Collateral circulation                              10034272   Pelvic venous thrombosis
  10007684                                  Carotid arterial embolus                                                               10059025                                Coronary bypass thrombosis                          10034324   Penile vein thrombosis
  10053003                                  Carotid artery bypass                                                                  10074896                                Device embolisation                                 10048874   Phlebectomy
  10048964                                  Carotid artery occlusion                                                               10064685                                Device occlusion                                    10073979   Portal vein cavernous transformation
  10066102                                  Carotid artery stent insertion                                                         10013033                                Diplegia                                            10058989   Portal vein occlusion
  10007688                                  Carotid artery thrombosis                                                              10013048                                Directional Doppler flow tests abnormal             10036206   Portal vein thrombosis
  10007692                                  Carotid endarterectomy                                                                 10013442                                Disseminated intravascular coagulation              10063909   Post procedural pulmonary embolism
  10053633                                  Cerebellar artery occlusion                                                            10013443                                Disseminated intravascular coagulation in newborn   10048591   Post thrombotic syndrome
  10008023                                  Cerebellar artery thrombosis                                                           10060839                                Embolic cerebral infarction                         10050902   Postoperative thrombosis
  10008088                                  Cerebral artery embolism                                                               10065680                                Embolic pneumonia                                   10036300   Postpartum venous thrombosis
  10008089                                  Cerebral artery occlusion                                                              10014498                                Embolic stroke                                      10037377   Pulmonary embolism
  10008092                                  Cerebral artery thrombosis                                                             10061169                                Embolism                                            10037410   Pulmonary infarction
  10065384                                  Cerebral hypoperfusion                                                                 10053601                                Foetal cerebrovascular disorder                     10037421   Pulmonary microemboli
  10058842                                  Cerebrovascular insufficiency                                                          10051269                                Graft thrombosis                                    10037437   Pulmonary thrombosis
  10061751                                  Cerebrovascular stenosis                                                               10019005                                Haemorrhagic cerebral infarction                    10068690   Pulmonary vein occlusion
  10069696                                  Coeliac artery occlusion                                                               10019013                                Haemorrhagic infarction                             10037458   Pulmonary veno-occlusive disease
  10050329                                  Coronary angioplasty                                                                   10019016                                Haemorrhagic stroke                                 10037459   Pulmonary venous thrombosis
  10052086                                  Coronary arterial stent insertion                                                      10055677                                Haemorrhagic transformation stroke                  10038547   Renal vein embolism
  10011077                                  Coronary artery bypass                                                                 10019023                                Haemorrhoids thrombosed                             10056293   Renal vein occlusion
  10011084                                  Coronary artery embolism                                                               10019465                                Hemiparesis                                         10038548   Renal vein thrombosis
  10011086                                  Coronary artery occlusion                                                              10019468                                Hemiplegia                                          10038907   Retinal vein occlusion
  10053261                                  Coronary artery reocclusion                                                            10062506                                Heparin-induced thrombocytopenia                    10038908   Retinal vein thrombosis
  10011091                                  Coronary artery thrombosis                                                             10019680                                Hepatic infarction                                  10068479   SI QIII TIII pattern
  10011101                                  Coronary endarterectomy                                                                10074494                                Hepatic vascular thrombosis                         10068122   Splenic vein occlusion
  10049887                                  Coronary revascularization                                                             10063868                                Implant site thrombosis                             10041659   Splenic vein thrombosis
  10075162                                  Coronary vascular graft occlusion                                                      10061216                                Infarction                                          10049446   Subclavian vein thrombosis
  10058729                                  Embolia cutis medicamentosa                                                            10065489                                Infusion site thrombosis                            10042567   Superior sagittal sinus thrombosis
  10014513                                  Embolism arterial                                                                      10022104                                Injection site thrombosis                           10058988   Superior vena cava occlusion
  10014648                                  Endarterectomy                                                                         10070754                                Inner ear infarction                                10042569   Superior vena cava syndrome
  10068365                                  Femoral artery embolism                                                                10073625                                Instillation site thrombosis                        10043570   Thrombophlebitis
  10052019                                  Femoral artery occlusion                                                               10022657                                Intestinal infarction                               10043581   Thrombophlebitis migrans
  10019635                                  Hepatic artery embolism                                                                10066087                                Intracardiac mass                                   10043586   Thrombophlebitis neonatal
  10051991                                  Hepatic artery occlusion                                                               10048620                                Intracardiac thrombus                               10043595   Thrombophlebitis superficial
  10019636                                  Hepatic artery thrombosis                                                              10027401                                Mesenteric vascular insufficiency                   10043605   Thrombosed varicose vein
  10063518                                  Hypothenar hammer syndrome                                                             10074583                                Mesenteric vascular occlusion                       10067270   Thrombosis corpora cavernosa
  10021338                                  Iliac artery embolism                                                                  10073734                                Microembolism                                       10044457   Transverse sinus thrombosis
  10064601                                  Iliac artery occlusion                                                                 10027925                                Monoparesis                                         10067740   Vascular graft
  10052989                                  Intra-aortic balloon placement                                                         10027926                                Monoplegia                                          10047193   Vena cava embolism
  10056382                                  Intraoperative cerebral artery occlusion                                               10030936                                Optic nerve infarction                              10048932   Vena cava filter insertion
  10060840                                  Ischaemic cerebral infarction                                                          10068239                                Pancreatic infarction                               10074397   Vena cava filter removal
  10061256                                  Ischaemic stroke                                                                       10066059                                Paradoxical embolism                                10047195   Vena cava thrombosis
  10051078                                  Lacunar infarction                                                                     10033885                                Paraparesis                                         10047209   Venogram abnormal
  10024242                                  Leriche syndrome                                                                       10033892                                Paraplegia                                          10062173   Venoocclusive disease
  10027394                                  Mesenteric arterial occlusion                                                          10033985                                Paresis                                             10047216   Venoocclusive liver disease
  10065560                                  Mesenteric arteriosclerosis                                                            10053351                                Peripheral revascularization                        10058990   Venous occlusion
  10027395                                  Mesenteric artery embolism                                                             10035092                                Pituitary infarction                                10062175   Venous operation
  10027396                                  Mesenteric artery stenosis                                                             10064620                                Placental infarction                                10068605   Venous recanalisation
  10071261                                  Mesenteric artery stent insertion                                                      10059829                                Pneumatic compression therapy                       10052964   Venous repair
  10027397                                  Mesenteric artery thrombosis                                                           10036204                                Portal shunt                                        10063389   Venous stent insertion
  10028596                                  Myocardial infarction                                                                  10066591                                Post procedural stroke                              10047249   Venous thrombosis
  10028602                                  Myocardial necrosis                                                                    10068628                                Prosthetic vessel implantation                      10067030   Venous thrombosis in pregnancy
  10033697                                  Papillary muscle infarction                                                            10049680                                Quadriparesis                                       10061408   Venous thrombosis limb
  10068035                                  Penile artery occlusion                                                                10037714                                Quadriplegia                                        10064602   Venous thrombosis neonatal
  10065608                                  Percutaneous coronary intervention                                                     10038470                                Renal infarct                                                  
  10062585                                  Peripheral arterial occlusive disease                                                  10072226                                Renal vascular thrombosis                                      
  10069379                                  Peripheral arterial reocclusion                                                        10051742                                Retinal infarction                                             
  10057518                                  Peripheral artery angioplasty                                                          10062108                                Retinal vascular thrombosis                                    
  10072561                                  Peripheral artery bypass                                                               10040621                                Shunt occlusion                                                
  10072562                                  Peripheral artery stent insertion                                                      10059054                                Shunt thrombosis                                               
  10072564                                  Peripheral artery thrombosis                                                           10058571                                Spinal cord infarction                                         
  10061340                                  Peripheral embolism                                                                    10041648                                Splenic infarction                                             
  10072560                                  Peripheral endarterectomy                                                              10074601                                Splenic thrombosis                                             
  10071642                                  Popliteal artery entrapment syndrome                                                   10074515                                Stoma site thrombosis                                          
  10066592                                  Post procedural myocardial infarction                                                  10058408                                Surgical vascular shunt                                        
  10058144                                  Postinfarction angina                                                                  10043337                                Testicular infarction                                          
  10036511                                  Precerebral artery occlusion                                                           10064961                                Thalamic infarction                                            
  10074717                                  Precerebral artery thrombosis                                                          10043530                                Thrombectomy                                                   
  10063731                                  Pulmonary artery therapeutic procedure                                                 10043540                                Thromboangiitis obliterans                                     
  10037340                                  Pulmonary artery thrombosis                                                            10043568                                Thrombolysis                                                   
  10072893                                  Pulmonary endarterectomy                                                               10043607                                Thrombosis                                                     
  10057493                                  Renal artery angioplasty                                                               10062546                                Thrombosis in device                                           
  10048988                                  Renal artery occlusion                                                                 10043626                                Thrombosis mesenteric vessel                                   
  10038380                                  Renal artery thrombosis                                                                10043634                                Thrombosis prophylaxis                                         
  10063544                                  Renal embolism                                                                         10067347                                Thrombotic cerebral infarction                                 
  10038826                                  Retinal artery embolism                                                                10043647                                Thrombotic stroke                                              
  10038827                                  Retinal artery occlusion                                                               10043742                                Thyroid infarction                                             
  10038831                                  Retinal artery thrombosis                                                              10045168                                Tumour embolism                                                
  10049768                                  Silent myocardial infarction                                                           10068067                                Tumour thrombosis                                              
  10049440                                  Spinal artery embolism                                                                 10061604                                Ultrasonic angiogram abnormal                                  
  10071316                                  Spinal artery thrombosis                                                               10045413                                Ultrasound Doppler abnormal                                    
  10074600                                  Splenic artery thrombosis                                                              10071652                                Umbilical cord thrombosis                                      
  10068677                                  Splenic embolism                                                                       10069922                                Vascular graft thrombosis                                      
  10066286                                  Stress cardiomyopathy                                                                  10049071                                Vascular operation                                             
  10059613                                  Stroke in evolution                                                                    10063382                                Vascular stent insertion                                       
  10042332                                  Subclavian artery embolism                                                             10058794                                Vasodilation procedure                                         
  10069695                                  Subclavian artery occlusion                                                            10070649                                Vessel puncture site thrombosis                                
  10042334                                  Subclavian artery thrombosis                                                           10066856                                Visual midline shift syndrome                                  
  10054156                                  Superior mesenteric artery syndrome                                                                                                                                                           
  10064958                                  Thromboembolectomy                                                                                                                                                                            
  10043645                                  Thrombotic microangiopathy                                                                                                                                                                    
  10043648                                  Thrombotic thrombocytopenic purpura                                                                                                                                                           
  10044390                                  Transient ischaemic attack                                                                                                                                                                    
  10062363                                  Truncus coeliacus thrombosis                                                                                                                                                                  
  10048965                                  Vertebral artery occlusion                                                                                                                                                                    
  10057777                                  Vertebral artery thrombosis                                                                                                                                                                   
  10047532                                  Visual acuity reduced transiently                                                                                                                                                             

^a)^ Medical Dictionary for Regulatory Activities

^b)^ Standardized MedDRA Queries

The mosaic plot of the two-way frequency table was constructed with the age-category (X) and primary disease (Y). A mosaic plot is divided into rectangles so that the vertical length of each rectangle is proportional to the proportion of the Y variable at each level of the X variable.

We assessed the association between CEPs and TE using the ROR, which is an established parameter for pharmacovigilance research. The ROR is the ratio of the odds of reporting an adverse event versus all other events associated with the drug of interest compared with the reporting odds for all other drugs present in the database \[[@pone.0182045.ref033]\]. We calculated the ROR using a two-by-two contingency table by defining the rows using CEPs and all other drugs and the columns using TE and all other adverse events ([Fig 1](#pone.0182045.g001){ref-type="fig"}). RORs are expressed as point estimates with 95% confidence intervals (CI). The detection of a signal was dependent on the signal indices exceeding a predefined threshold. Safety signals are considered significant when the ROR estimates and the lower limits of the corresponding 95% CI exceed 1. At least 2 cases are required to define a signal \[[@pone.0182045.ref033],[@pone.0182045.ref034]\].

![Two by two table used for the calculation of reporting odds ratios and proportional reporting ratio.](pone.0182045.g001){#pone.0182045.g001}

Proportional reporting ratios (PRRs) are measures of disproportionality used for detecting signals in SRS databases \[[@pone.0182045.ref035]\]. PRRs are calculated from the same 2 × 2 tables and the ROR is identical to the calculation of relative risk (RR) from a cohort study, i.e., \[a / (a + c)\] / \[b / (b + d)\]. If the drug and adverse event are independent, the expected value of the PRR is 1. The minimum criteria for signal detection are as follows: 3 or more cases, PRR of at least 2, and Chi-square of at least 4.

Time-to-onset duration of the data from the JADER database was calculated from the time of the patient's first prescription to the occurrence of the AE. The median duration, quartiles, and Weibull shape parameters (WSPs) were used to evaluate the dates from administration to development of TE \[[@pone.0182045.ref027],[@pone.0182045.ref036]--[@pone.0182045.ref038]\]. The WSP test is used for the statistical analysis of time-to-onset data and can describe the non-constant rate of the incidence of AE reactions \[[@pone.0182045.ref024],[@pone.0182045.ref039]\]. The scale parameter α of the Weibull distribution determines the scale of the distribution function. A larger scale value stretches the distribution. A smaller scale value shrinks the data distribution. The shape parameter β of the Weibull distribution indicates the hazard without a reference population. When β is equal to 1, the hazard is estimated to be constant over time. When β is greater than 1 and the 95% CI of β excludes 1, the hazard is considered to increase over time. When β is smaller than 1 and the 95% CI of β excludes 1, the hazard is considered to decrease over time \[[@pone.0182045.ref039]\]. The data analyses were performed using JMP 11.2 (SAS Institute Inc., Cary, NC, USA).

Association rule mining {#sec003}
-----------------------

The association rule mining approach attempts to search the frequent items in databases and discover interesting relationships between variables. Given a set of transactions ***T*** (each transaction is a set of items), an association rule can be expressed as X -\> Y, where X and Y are mutually exclusive sets of items \[[@pone.0182045.ref040]\]. The rule's statistical significance and strength are measured by the *support* and *confidence*, respectively. *Support* is defined as the percentage of transactions in the data that contain all items in both the antecedent (left-hand-side of rule: lhs) and the consequent of the rule (right-hand-side of rule: rhs) \[[@pone.0182045.ref040]\]. The support indicates how frequently the rule occurs in the transaction. The formula for calculating *support* is as follows: $$Support~ = \text{P}\left( {\text{X~} \cap \text{~Y}} \right) = \left\{ {\text{X~} \cap \text{~Y}} \right\}/\left\{ \text{D} \right\}$$ D is the total number of the transaction. *Confidence* corresponds to the conditional probability P (Y\|X). A rule with high *confidence* is important because it provides an accurate prediction of the association of the items in the rule. The formula for calculating *confidence* is as follows: $$Confidence\  = \text{P}\left( {\text{X~} \cap \text{~Y}} \right)/\text{P}\left( \text{X} \right)$$ *Lift* represents the ratio of probability. For a given rule, X and Y occur together to the multiple of the two individual probabilities for X and Y; that is, $$Lift~ = \text{P}\left( {\text{X~} \cap \text{~Y}} \right)/\text{P}\left( \text{X} \right)\text{~P}\left( \text{Y} \right)$$ Since P(Y) appears in the denominator of the *lift* measure, the *lift* can be expressed as the confidence divided by P(Y). The *lift* can be evaluated as follows: *lift* = 1, if X and Y are independent; *lift* \> 1, if X and Y are positively correlated; *lift* \< 1, if X and Y are negatively correlated. We performed these analyses using the apriori function of the *arules* library in the *arules* package of R version 3.3.3 software \[[@pone.0182045.ref041]\].

Results {#sec004}
=======

The JADER database contained 338,224 reports from April 2004 to November 2014. The number of reports including TE was 14,593. The RORs (95% CI) of agents with Dro-EE, Ne-EE, Lev-EE, Des-EE, and Nor-EE were 56.2 (44.3--71.4), 29.1 (23.5--35.9), 42.9 (32.3--57.0), 44.7 (32.7--61.1), and 38.6 (26.3--56.7), respectively ([Table 2](#pone.0182045.t002){ref-type="table"}). The PRRs (95% CI) of Dro-EE, Ne-EE, Lev-EE, Des-EE, and Nor-EE were 16.8 (13.2--21.3), 13.2 (10.7--16.4), 15.4 (11.6--20.4), 15.6 (11.4--21.3), and 14.8 (10.0--21.7), respectively ([Table 2](#pone.0182045.t002){ref-type="table"}).

10.1371/journal.pone.0182045.t002

###### Number of reports, proportional reporting ratio and reporting odds ratio of thromboembolism [^a)^](#t002fn001){ref-type="table-fn"}.

![](pone.0182045.t002){#pone.0182045.t002g}

  Drug                                                        Age (years old)   Case    Total    Non-case   Reporting ratio of thromboembolism (%)   PRR (95% CI)                             χ2                                       ROR (95% CI)
  ----------------------------------------------------------- ----------------- ------- -------- ---------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ------------------------------------------
  Total                                                                         14593   338224                                                                                                                                         
  All CEPs [^b)^](#t002fn002){ref-type="table-fn"}                              744     1163     419        64.0                                     15.6 (13.8−17.6)                         10046.1                                  41.4 (36.7−46.8)
                                                              10−19             14      30       16         46.7                                     10.8 (5.3−22.2)                          120.3                                    19.4 (9.5−39.8)
                                                              20−29             113     198      85         57.1                                     13.3 (10.1−17.7)                         1322.9                                   29.7 (22.4−39.4)
                                                              30−39             243     355      112        68.5                                     16.1 (12.9−20.2)                         3525.3                                   48.9 (39.1−61.2)
                                                              40−49             298     400      102        74.5                                     17.6 (14.1−22.1)                         4761.4                                   66.1 (52.8−82.8)
                                                              50−59             35      52       17         67.3                                     15.6 (8.8−27.9)                          484.7                                    45.8 (25.6−81.7)
  Drospirenone-EE [^c)^](#t002fn003){ref-type="table-fn"}                       237     332      95         71.4                                     16.8 (13.2−21.3)                         3604.9                                   56.2 (44.3−71.4)
                                                              10−19             7       12       5          58.3                                     13.5 (4.3−42.6)                          72.2                                     31.1 (9.9−97.9)
                                                              20−29             37      52       15         71.2                                     16.5 (9.1−30.1)                          546.7                                    54.8 (30.1−99.9)
                                                              30−39             79      98       19         80.6                                     18.8 (11.4−31.0)                         1363.8                                   92.7 (56.2−153.0)
                                                              40−49             86      101      15         85.1                                     19.8 (11.5−34.4)                         1579.5                                   127.9 (73.9−221.4)
                                                              50−59             12      14       2          85.7                                     19.9 (4.4−88.8)                          205.4                                    133.2 (29.8−595.1)
  Norethisterone-EE [^c)^](#t002fn003){ref-type="table-fn"}                     198     351      153        56.4                                     13.2 (10.7−16.4)                         2297.2                                   29.1 (23.5−35.9)
                                                              10−19             2       2        0          100.0                                    −[\*](#t002fn004){ref-type="table-fn"}   −[\*](#t002fn004){ref-type="table-fn"}   −[^†^](#t002fn006){ref-type="table-fn"}
                                                              20−29             20      54       34         37.0                                     8.6 (4.9−14.9)                           132.2                                    13.1 (7.5−22.7)
                                                              30−39             54      99       45         54.5                                     12.7 (8.5−18.8)                          593.1                                    26.7 (18.0−39.7)
                                                              40−49             108     155      47         69.7                                     16.3 (11.5−22.9)                         1588.9                                   51.3 (36.4−72.3)
                                                              50−59             6       12       6          50.0                                     11.6 (3.7−35.9)                          50.1                                     22.2 (7.2−68.8)
  Levonorgestrel-EE [^c)^](#t002fn003){ref-type="table-fn"}                     140     213      73         65.7                                     15.4 (11.6−20.4)                         1932.2                                   42.9 (32.3−57.0)
                                                              10−19             1       4        3          25.0                                     −[\*](#t002fn004){ref-type="table-fn"}   −[\*](#t002fn004){ref-type="table-fn"}   −[\*\*](#t002fn005){ref-type="table-fn"}
                                                              20−29             19      32       13         59.4                                     13.8 (6.8−27.9)                          221.9                                    32.5 (16.0−65.7)
                                                              30−39             54      77       23         70.1                                     16.3 (10.0−26.6)                         792.2                                    52.3 (32.1−85.2)
                                                              40−49             56      76       20         73.7                                     17.1 (10.3−28.6)                         869.3                                    62.3 (37.4−103.9)
                                                              50−59             7       11       4          63.6                                     14.8 (4.3−50.4)                          79.9                                     38.8 (11.4−132.7)
  Desogestrel-EE [^c)^](#t002fn003){ref-type="table-fn"}                        118     177      59         66.7                                     15.6 (11.4−21.3)                         1652.6                                   44.7 (32.7−61.1)
                                                              10−19             3       7        4          42.9                                     9.9 (2.2−44.4)                           16.7                                     16.6 (3.7−74.3)
                                                              20−29             25      43       18         58.1                                     13.5 (7.4−24.7)                          288.9                                    30.9 (16.8−56.6)
                                                              30−39             43      54       11         79.6                                     18.5 (9.5−35.9)                          723.9                                    87.0 (44.8−168.6)
                                                              40−49             34      43       9          79.1                                     18.4 (8.8−38.3)                          564.2                                    84.0 (40.3−175.1)
                                                              50−59             2       3        1          66.7                                     −[\*](#t002fn004){ref-type="table-fn"}   −[\*](#t002fn004){ref-type="table-fn"}   44.4 (4.0−489.3)
  Norgestrel-EE [^c)^](#t002fn003){ref-type="table-fn"}                         71      112      41         63.4                                     14.8 (10.0−21.7)                         932.9                                    38.6 (26.3−56.7)
                                                              10−19             1       5        4          20.0                                     −[\*](#t002fn004){ref-type="table-fn"}   −[\*](#t002fn004){ref-type="table-fn"}   −[\*\*](#t002fn005){ref-type="table-fn"}
                                                              20−29             12      19       7          63.2                                     14.6 (5.8−37.2)                          145.4                                    38.1 (15.0−96.7)
                                                              30−39             25      39       14         64.1                                     14.9 (7.7−28.6)                          323.4                                    39.7 (20.6−76.3)
                                                              40−49             22      33       11         66.7                                     15.5 (7.5−31.9)                          295.9                                    44.4 (21.5−91.6)
                                                              50−59             8       12       4          66.7                                     15.5 (4.7−51.3)                          98.4                                     44.4 (13.4−147.4)

^a)^ SMQ code (20000082, 20000083, and 20000084)

^b)^ CEP: Combined Estrogen-progestin Preparations.

^c)^ EE: Ethinyl Estradiol.

\* Number of cases \< 3.

\*\* Number of cases \< 2.

^†^Non-case was not reported.

In the mosaic plot, Dro-EE and Nor-EE were primarily administered to patients with dysmenorrhea and endometriosis, respectively ([Fig 2](#pone.0182045.g002){ref-type="fig"}). The ROR and 95% CI of patients stratified by age in the 10--19, 20--29, 30--39, 40--49, and 50--59 -year-old groups were 19.4 (9.5--39.8), 29.7 (22.4--39.4), 48.9 (39.1--61.2), 66.1 (52.8--82.8), and 45.8 (25.6--81.7), respectively ([Table 2](#pone.0182045.t002){ref-type="table"}).

![Mosaic plot of thromboembolism by combined estrogen-progestin preparations.](pone.0182045.g002){#pone.0182045.g002}

The analysis of time-to-onset profiles revealed that the median values (25%--75%) of thrombosis caused by agents containing Dro-EE, Ne-EE, Lev-EE, Des-EE, and Nor-EE were 150.0 (75.3--314.0), 128.0 (27.0--279.0), 204.0 (44.0--660.0), 142.0 (41.3--344.0), and 16.5 (8.8--32.0) days, respectively ([Table 3](#pone.0182045.t003){ref-type="table"}). The WSP β (95% CI) for Dro-EE, Ne-EE, Lev-EE, Des-EE, and Nor-EE were 1.12 (1.01--1.23), 0.81 (0.72--0.91), 0.81 (0.68--0.96), 0.92 (0.78--1.07), and 0.62 (0.50--0.75), respectively ([Table 3](#pone.0182045.t003){ref-type="table"}).

10.1371/journal.pone.0182045.t003

###### Quartiles and parameter of Weibull distribution and failure pattern for combined estrogen-progestin preparations.

![](pone.0182045.t003){#pone.0182045.t003g}

  Drugs                          Case reports (n)   Median (lower−upper quartile)(day)   Scale parameter, α (95% CI)   Shape parameter, β (95% CI)
  ------------------------------ ------------------ ------------------------------------ ----------------------------- -----------------------------
  *Total*                        670                135.0 (40.0−305.3)                   202.0 (184.0−221.5)           0.86 (0.81−0.91)
  Drospirenone-EE                240                150.0 (75.3−314.0)                   223.8 (198.2−252.2)           1.12 (1.01−1.23)
  Norethisterone-EE              185                128.0 (27.0−279.0)                   186.3 (153.8−224.6)           0.81 (0.72−0.91)
  Levonorgestrel-EE              95                 204.0 (44.0−660.0)                   281.4 (214.7−365.5)           0.81 (0.68−0.96)
  Desogestrel-EE                 100                142.0 (41.3−344.0)                   225.9 (179.1−282.8)           0.92 (0.78−1.07)
  Norgestrel-EE                  50                 16.5 (8.8−32.0)                      38.3 (23.3−61.8)              0.62 (0.50−0.75)
  *Subgroup for contraception*                                                                                         
  Subtotal                       67                 244.0 (104.0−730.0)                  333.8 (258.5−427.0)           1.03 (0.83−1.25)
  Drospirenone-EE                −                  −                                    −                             −
  Norethisterone-EE              −                  −                                    −                             −
  Levonorgestrel-EE              42                 245.0 (172.5−730.0)                  408.8 (303.1−545.2)           1.14 (0.86−1.46)
  Desogestrel-EE                 25                 183.0 (31.5−370.5)                   238.1 (150.7−366.6)           0.99 (0.70−1.35)
  Norgestrel-EE                  −                  −                                    −                             −
  *Subgroup for dysmenorrhea*                                                                                          
  Subtotal                       324                137.0 (58.3−292.3)                   208.0 (184.3−234.1)           0.96 (0.88−1.05)
  Drospirenone-EE                204                150.0 (69.3−345.8)                   223.5 (195.1−255.3)           1.09 (0.97−1.21)
  Norethisterone-EE              88                 126.0 (27.8−287.3)                   200.2 (151.2−262.6)           0.81 (0.68−0.95)
  Levonorgestrel-EE              13                 88.0 (14.0−250.0)                    166.1 (91.2−291.3)            1.27 (0.71−2.05)
  Desogestrel-EE                 12                 135.5 (79.0−262.0)                   217.4 (126.0−363.5)           1.28 (0.79−1.87)
  Norgestrel-EE                  7                  26.0 (16.0−197.0)                    87.5 (26.0−273.4)             0.85 (0.42−1.47)
  *Subgroup for endomeriosis*                                                                                          
  Subtotal                       88                 123.0 (40.3−329.8)                   219.3 (158.3−300.7)           0.70 (0.59−0.82)
  Drospirenone-EE                13                 134.0 (76.5−314.0)                   184.2 (107.3−305.4)           1.25 (0.75−1.91)
  Norethisterone-EE              57                 106.0 (23.5−253.0)                   167.9 (116.0−239.4)           0.78 (0.63−0.95)
  Levonorgestrel-EE              6                  240.0 (6.0−669.3)                    502.1 (192.9−1275.4)          1.55 (0.54−3.36)
  Desogestrel-EE                 9                  679.0 (125.0−730.0)                  563.4 (353.9−876.8)           1.93 (0.94−3.48)
  Norgestrel-EE                  3                  19.0 (19.0−20.0)                     −                             −

The association rule mining technique was applied to TE (as consequent) using demographic data such as age category and patient history. The apriori algorithm extracts frequent combinations from a large database to efficiently find sets of adverse events that occur more frequently than the minimum *support* threshold (defined as 0.00001 in this study). This generates sets of adverse drug reactions with the minimum *confidence* threshold (defined as 0.9 in this study). Furthermore, the maximum size of mined frequent item sets (*maxlen*: a parameter in the *arules* package) was restricted to 3. The result of the mining algorithm was a set of 12 rules ([Table 4](#pone.0182045.t004){ref-type="table"}). The *support*, *confidence*, and *lift* of each association rule are summarized in [Table 4](#pone.0182045.t004){ref-type="table"}; the association rules up to the twelfth position in descending order of the *support* are shown in [Table 4](#pone.0182045.t004){ref-type="table"}. {Des-EE, uterine leiomyoma} -\> {TE} demonstrated a high *support* value ([Table 4](#pone.0182045.t004){ref-type="table"}, id \[1\]). The association rules of {sodium ferrous citrate, Dro-EE} -\> {TE}, {Dro-EE, hypoferric anemia} -\> {TE}, and {Lev-EE, anemia} -\> {TE} with high scores for *lift* and *support* were demonstrated ([Table 4](#pone.0182045.t004){ref-type="table"} (id \[2\], \[8\], \[11\], [Fig 3](#pone.0182045.g003){ref-type="fig"}). Additionally, the association rules of the combination of {smoking, Nor-EE} were high ([Table 4](#pone.0182045.t004){ref-type="table"}, id \[3\]).

10.1371/journal.pone.0182045.t004

###### Association parameters of rules (sorted by support).

![](pone.0182045.t004){#pone.0182045.t004g}

  id       lhs [^a)^](#t004fn001){ref-type="table-fn"}       rhs [^b)^](#t004fn002){ref-type="table-fn"}   support    confidence   Lift
  -------- --------------------------------------------- --- --------------------------------------------- ---------- ------------ -------
  \[1\]    {Desogestrel-EE, uterine leiomyoma}           →   {thromboembolism}                             0.000030   0.91         21.07
  \[2\]    {sodium ferrous citrate, Drospirenone-EE}     →   {thromboembolism}                             0.000030   1.00         23.18
  \[3\]    {smoking, Norethisterone-EE}                  →   {thromboembolism}                             0.000021   1.00         23.18
  \[4\]    {Desogestrel-EE, Levonorgestrel-EE}           →   {thromboembolism}                             0.000018   1.00         23.18
  \[5\]    {Drospirenone-EE, asthma}                     →   {thromboembolism}                             0.000018   1.00         23.18
  \[6\]    {Amlodipine besylate, Drospirenone-EE}        →   {thromboembolism}                             0.000018   1.00         23.18
  \[7\]    {Drospirenone-EE, hypertension}               →   {thromboembolism}                             0.000018   1.00         23.18
  \[8\]    {Drospirenone-EE, hypoferric anemia}          →   {thromboembolism}                             0.000015   1.00         23.18
  \[9\]    {Norethisterone-EE, Norgestrel-EE}            →   {thromboembolism}                             0.000012   1.00         23.18
  \[10\]   {Levonorgestrel-EE, toki-shakuyaku-san}       →   {thromboembolism}                             0.000012   1.00         23.18
  \[11\]   {Levonorgestrel-EE, anemia}                   →   {thromboembolism}                             0.000012   1.00         23.18
  \[12\]   {alprazolam, Norethisterone-EE}               →   {thromboembolism}                             0.000012   1.00         23.18

^a)^ left-hand-sides of rule (antecedents)

^b)^ right-hand-side (consequents)

![Association rules of thromboembolism by combined estrogen-progestin preparations.\
The plot represents items and rules as vertices connected with directed edges. Relation parameters are typically added to the plot as labels on the edges or by varying the color or width of the arrows indicating the edges.](pone.0182045.g003){#pone.0182045.g003}

Discussion {#sec005}
==========

The RORs and PRRs suggested that all CEPs were associated with an increased risk of TE. Several studies demonstrated that the increase in VTE risk after administration of Dro-EE or Des-EE was greater than that after administration of Lev-EE \[[@pone.0182045.ref006],[@pone.0182045.ref008],[@pone.0182045.ref011],[@pone.0182045.ref015],[@pone.0182045.ref042]\]. The risk of VTE might be associated with the type of progestin, the amount of estrogen, or the pharmacological activity of estrogen \[[@pone.0182045.ref006],[@pone.0182045.ref007]\]. In contrast, Odlind et al. suggested that those associations might be subject to bias \[[@pone.0182045.ref043],[@pone.0182045.ref044]\]. Whereas some studies indicated that Des-EE reduced the risk of ATE compared to other CEPs, other studies did not \[[@pone.0182045.ref002],[@pone.0182045.ref023]\]. Lidegaard et al. found the risk of ATE decreased with lower doses of estrogen \[[@pone.0182045.ref023]\]. We did not observe significant differences in the RORs among Dro-EE, Nor-EE, Lev-EE, and Des-EE. We do not have a conclusive explanation for the differences in TE risk between the various progestins in low-dose CEPs.

The median time to TE onset induced by Nor-EE, which contained the highest amount of EE (50 μg), was the shortest time to onset among the CEPs (16.5 days). EE enhances the effects of the procoagulation factors 2, 7, 9, 10, 12, 13, and fibrinogen, while reducing natural anticoagulant protein S and antithrombin, and acts as a procoagulant \[[@pone.0182045.ref002],[@pone.0182045.ref045]\]. The effects of EE were reported to be dose-dependent \[[@pone.0182045.ref002]\]. With an estrogen dose of 30 μg as the reference category, the thrombotic risk was 0.8 (95% CI 0.5 to 1.2) for an estrogen dose of 20 μg and 1.9 (1.1 to 3.4) for a dose of 50 μg \[[@pone.0182045.ref011]\]. In contrast, progestin has no effect on coagulation factor levels \[[@pone.0182045.ref002]\]. One plausible reason for the "short" median time to TE onset induced by Nor-EE might be the high amount of EE in Nor-EE in our study. However, the mechanism of development of thrombosis is poorly understood. It may be due to the differential effects on sex hormone binding globulin, anticoagulant protein S resistance in early OC use, or the unmasking of an underlying inherited coagulation disorder \[[@pone.0182045.ref004]\]. CEPs have several metabolic effects on lipid, carbohydrate, and hemostatic parameters \[[@pone.0182045.ref003]\]. To reveal the mechanism of the short time to onset of TE by Nor-EE, further pharmacological study is necessary.

The WSP β of Ne-EE, Lev-EE, and Nor-EE was less than 1, which indicated an early failure type, and indicated that TE caused by these CEPs might decrease over time. It was reported that the risk of VTE decreased with prolonged administration \[[@pone.0182045.ref046]--[@pone.0182045.ref048]\] and recovered to the level of non-users of CEPs within 3 months after discontinuation \[[@pone.0182045.ref015]\].

In our study, the median occurrence of TE for all CEPs was within 3 months; however, several instances of VTE were observed after 3 months. The risks of VTE were reported to be observed within 4 months following CEP administration \[[@pone.0182045.ref015]\]. These results corresponded with those of previous studies and confirmed the necessity of long-term observation after the administration of these drugs.

In the association rule mining, because the *lift* values of two combined items, CEPs and anemia-related items, including iron pill administration, were high, patients with anemia had a potential risk of TE when using CEPs. Recently, an association between anemia and cerebral venous thrombosis was reported \[[@pone.0182045.ref049]\]. Therefore, anemia patients should be monitored carefully. The *lift* values of the two combined items, {smoking, Nor-EE}, were also high enough to suggest an association. This information demonstrated that smoking while taking CEPs may increase the risk of TE.

Association rule mining is one of the most important tasks in data mining and various effective algorithms have been proposed. Several groups have conducted the performance evaluation of the association rule mining algorithms, such as apriori, Frequent Pattern (FP)-Growth, and Eclat, by execution time or those with higher confidence, lift, and conviction values. Apriori is a level-wise, breadth-first algorithm that counts transactions, generates candidates, and discovers frequent itemsets by the exploitation of user-specified support and confidence measures. In a large quantity of itemsets, the algorithm requires more space and time; consequently, the complexity of the algorithm increases \[[@pone.0182045.ref050]\]. The FP-Growth algorithm was proposed as an alternative to the apriori-based approach by Han \[[@pone.0182045.ref051],[@pone.0182045.ref052]\]. The basic concept of the FP-Growth algorithm consists of the construction of an FP-tree for all the transactions. FP-Growth encodes the data set by using a compact data structure called an FP-tree, which can save considerable amounts of memory in transaction storage \[[@pone.0182045.ref052],[@pone.0182045.ref053]\]. The Eclat algorithm uses equivalence classes, depth-first search, and set intersection instead of counting. Eclat is a depth-first search-based algorithm that uses a vertical database layout \[[@pone.0182045.ref054]\]. It also solves the frequent itemset problem. However, the performance by each algorithm differs owing to various parameters, such as the size of itemset and the structure of database. We consider that the relative merits of the algorithms have not yet been settled.

An apriori algorithm is designed to efficiently identify association rules in large databases and is the most classical algorithm for mining frequent item sets \[[@pone.0182045.ref055]\]. This algorithm has recently been used for the analysis of AEs in the JADER and US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and confirmed its usefulness for pharmacovigilance \[[@pone.0182045.ref029]--[@pone.0182045.ref031]\]. Therefore, we used an apriori algorithm.

The numerous known risk factors for TE in women are as follows: advanced age \[[@pone.0182045.ref005],[@pone.0182045.ref006],[@pone.0182045.ref011]\], high body mass index \[[@pone.0182045.ref014],[@pone.0182045.ref047],[@pone.0182045.ref056]--[@pone.0182045.ref060]\], smoking \[[@pone.0182045.ref020],[@pone.0182045.ref061]--[@pone.0182045.ref065]\], breast cancer, migraine, hypertension, and medical history of a cardiovascular event \[[@pone.0182045.ref001],[@pone.0182045.ref066]\]. CEP use should be discouraged among women older than 35 years who smoke because they have an increased risk of arterial vascular disease when using CEP \[[@pone.0182045.ref010]\]. CEP users should have their blood pressure routinely monitored and smoking cessation should be encouraged in older women. Clinicians should monitor for any symptoms suggestive of stroke, myocardial infarction, or venous thrombosis and discontinue the agent immediately if any symptoms occur during the first 3 months of CEP use. From our results, Nor-EE users should be closely monitored for the first 2 to 3 weeks. Regarding the prescribing of CEPs, clinicians should consider a woman\'s risk factors for TE. The choice of an appropriate CEP should be made by considering the need to minimize the risk of TE, patient preference, and available alternatives.

Like the JADER database, the FAERS database is an SRS and is the largest and best-known AEs database worldwide. Therefore, the FDA uses it for pharmacovigilance activities, such as looking for new safety concerns that might be related to a drug. The FAERS database files are publicly available on the FDA web site (open.fda.gov/data/faers/) \[[@pone.0182045.ref033]\]. FAERS includes information about the country where the AEs occurred. From our preliminary analysis of the FAERS database from April 2004 to November 2014, the total number of reported cases in the FAERS database was 6,165,659 and the number of reports from the US and Japan was 3,652,497 (59.2%) and 275,268 (4.5%), respectively (detailed data not shown). The number of reported AEs in the JADER (338,224 in this study) was greater than that in the FAERS (275,268 from Japan). Nomura et al. reported that there are differences in the reported number of AEs between JADER and FAERS, but the reports that were common between the FAERS and JADER were uncertain \[[@pone.0182045.ref067]\]. SRS databases mostly depend on the compliance of pharmaceutical companies to report according to regulatory requirements. Each company has its own operational rules for AE reports, which makes it impossible for researchers to validate the contents of SRS databases \[[@pone.0182045.ref067]\]. Regional differences in drug prescriptions or genetic backgrounds may be related to AEs. However, we did not analyze this issue further.

The JADER database does not contain detailed background information regarding patients' body mass index, smoking, or accurate medical history, such as migraine and cardiovascular disease. Furthermore, SRS has several limitations, including under-reporting, over-reporting, missing data, bias, confounding factors, and lack of a control population as a reference group \[[@pone.0182045.ref034]\]. Further epidemiological studies for confirmation might be required.

Several pharmacovigilance indexes have been developed to detect drug-associated AEs, including the ROR used by the PMDA and the Netherlands Pharmacovigilance Centre (Lareb), the PRR used by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom (UK), the information component (IC) used by WHO, and the empirical Bayes geometric mean (EBGM) used by the FDA. The multi-item gamma poisson shrinker (MGPS) method is a disproportionality method that utilizes an empirical Bayesian model to detect the magnitude of drug-event associations in drug safety databases \[[@pone.0182045.ref068],[@pone.0182045.ref069]\]. MGPS calculates adjusted reporting ratios for pairs of drug event combinations. The adjusted reporting ratio values are termed the EBGM. Although many studies regarding the performance, accuracy, and reliability of different data mining algorithms are in progress, there is no recognized *gold standard* methodology. We did not analyze using the EBGM, but this might be a future consideration.

The ROR is defined as the ratio of the odds of reporting of one specific event versus all other events for a given drug compared to the reporting odds for all other drugs present in the database. Basically, the higher the value, the stronger the disproportion appears to be. The ROR indicates an increased risk of AE reporting and not a risk of AE occurrence. Therefore, the ROR does not allow risk quantification, but only offers a rough indication of signal strength and is only relevant to the hypothesis \[[@pone.0182045.ref024],[@pone.0182045.ref033],[@pone.0182045.ref034]\]. The ROR is a clear and easily applicable technique that allows for the control of confounding factors through logistic regression analysis \[[@pone.0182045.ref027],[@pone.0182045.ref070]--[@pone.0182045.ref072]\]. An additional advantage of using the ROR is that non-selective underreporting of a drug or AE has no influence on the value of the ROR compared with the population of patients experiencing an AE \[[@pone.0182045.ref073]\]. Therefore, we selected first the ROR as a pharmacovigilance index in this study.

ROR and PRR are both measures of disproportionality used to detect signals in SRS databases. In our study, the tendencies of the results from the RORs and the PRRs for signal detection were similar. Evans et al. suggested that the PRR might be much less error prone than the ROR \[[@pone.0182045.ref035]\]. In contrast, Rothman et al. proposed that SRS should be treated as a data source for a case-control study, thereby excluding from the control series those events that may be related to drug exposure. Therefore, the ROR may offer an advantage over PRR by estimating the relative risk \[[@pone.0182045.ref074]\]. However, this apparent superiority has been called into question \[[@pone.0182045.ref075]\]. Van Puijenbroek et al. concluded that, in practice, there is no important difference between the ROR and PRR measures for pharmacovigilance \[[@pone.0182045.ref034]\]. A judgment on the validity and utility of these measures should be based on comparison of their sensitivity, specificity, and predictive values in signal detection from a real dataset.

The aforementioned limitations inherent to the SRS should be recognized in the interpretation of the results from the JADER database. We stress that our results do not provide any justification for the restriction of CEP use because the benefits and tolerability of CEPs have been accepted worldwide.

Conclusion {#sec006}
==========

This study was the first to evaluate the correlation between CEP and TE using an SRS analysis strategy. Despite the limitations inherent to SRS, we showed the potential risk of TE during CEP use in a real-life setting. The present analysis demonstrated that the incidence of TE with Nor-EE use should be closely monitored for a short onset (within 3 weeks). Patients with anemia who are using CEPs might be advised to adhere to an appropriate care plan. We recommend the close monitoring of patients, and those who experience any symptoms suggestive of TE should be advised to discontinue administration.
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